Polymorphism rs2383207 of CDKN2B-AS and Susceptibility to Atherosclerosis: A Mini Review

Polymorphism rs2383207 of CDKN2B-AS and Susceptibility to Atherosclerosis: A Mini Review

We conducted this meta-analysis to estimate associations between CDKN2B antisense (CDKN2B-AS) rs2383207 polymorphism and susceptibility to atherosclerosis. A systematic literature research of Google Scholar and PubMed was performed to identify eligible studies. Overall, eight studies were included f...

Full description

Bibliographic Details
Main Authors:	Sofia Vladimorovna Timofeeva, Tatiana Alexandrovna Sherchkova, Tatiana Pavlovna Shkurat
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Non-Coding RNA
Subjects:	CDKN2B antisense (CDKN2B-AS) lncRNA gene polymorphisms atherosclerosis meta-analysis
Online Access:	https://www.mdpi.com/2311-553X/8/6/78

Similar Items

Deoxyribonucleic acid methylation in the enhancer region of the CDKN2A/2B and CDKN2B-AS1 genes in blood vessels and cells in patients with carotid atherosclerosis
by: Yu. A. Koroleva, et al.
Published: (2020-11-01)

CDKN2B-AS1 polymorphism rs1333049 is associated with advanced carotid artery atherosclerosis in a Slovenian population
by: Jernej Letonja, et al.
Published: (2024-09-01)

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
by: E. Genescà, et al.
Published: (2018-07-01)

Effect of 9p21.3 (lncRNA and CDKN2A/2B) variant on lipid profile
by: Baozhu Wei, et al.
Published: (2022-09-01)

Association of CDKN2A/B gene polymorphisms (rs10811661 and rs2383208) with type 2 diabetes mellitus in a sample of Iraqi population
by: Hussein K. Fadheel, et al.
Published: (2022-03-01)

CDKN2B-AS1 Promotes Malignancy as a Novel Prognosis-Related Molecular Marker in the Endometrial Cancer Immune Microenvironment
by: Di Yang, et al.
Published: (2021-10-01)

Genetic study of the CDKN2A and CDKN2B genes in renal cell carcinoma patients
by: Nattaradee Kiatprungvech, et al.
Published: (2024-05-01)

The Association of SNPs Located in the CDKN2B-AS1 and LPA Genes With Carotid Artery Stenosis and Atherogenic Stroke
by: Anetta Lasek-Bal, et al.
Published: (2019-11-01)

High Positive Correlations between <i>ANRIL</i> and <i>p16</i>-<i>CDKN2A</i>/<i>p15</i>-<i>CDKN2B</i>/<i>p14</i>-<i>ARF</i> Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an <i>ANRIL–ARF</i> Bidirectional Promoter
by: Kinan Drak Alsibai, et al.
Published: (2019-08-01)

Expression of cyclin-dependent kinase inhibitors (CDKN1, CDKN5) in developmentally competent and incompetent porcine oocytes
by: H. Piotrowska, et al.
Published: (2013-09-01)

CDKN2B-AS1 gene rs4977574 polymorphism in the severity of coronary artery disease in the Kazakh population
by: Askhat Myngbay, et al.
Published: (2023-12-01)

<i>CDKN2A/B</i> Homozygous Deletions in Astrocytomas: A Literature Review
by: Alexander Yuile, et al.
Published: (2023-06-01)

DNA methylation analysis of the tumor suppressor gene CDKN2B in Brazilian leukemia patients
by: Patrícia Santos Pereira Lima, et al.
Published: (2008-01-01)

LncRNA AC006064.4–201 serves as a novel molecular marker in alleviating cartilage senescence and protecting against osteoarthritis by destabilizing CDKN1B mRNA via interacting with PTBP1
by: Panyang Shen, et al.
Published: (2023-04-01)

LncRNA CDKN2B-AS1 Promotes Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma via Sponging miR-424-5p
by: Shen X, et al.
Published: (2020-08-01)

Genetic alterations of CDX1, CYLD and CDKN2B genes in CRC
by: Seyed Mohammad Taghi Hamidian, et al.
Published: (2021-09-01)

Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival
by: Shahad W. Kattan, et al.
Published: (2021-04-01)

Association of CDKN2A/CDKN2B Gene Polymorphisms with Increased Susceptibility to Intracranial Aneurysm in a Chinese Han Population
by: Cui X, et al.
Published: (2021-05-01)

Evaluation of AURKA rs2273535 and CDKN1B rs34330 Polymorphisms Association with the Risk of Breast Cancer
by: Atefeh Liravi, et al.
Published: (2022-11-01)

CDKN2B‐AS (rs2891168), SOD2 (rs4880), and PON1 (rs662) polymorphisms and susceptibility to coronary artery disease and type 2 diabetes mellitus in Iranian patients: A case‐control study
by: Abolfazl Yari, et al.
Published: (2023-11-01)

CDKN2B methylation is associated with carotid artery calcification in ischemic stroke patients
by: Shuyu Zhou, et al.
Published: (2016-12-01)

Exosomes released from M2 macrophages transfer miR‐221‐3p contributed to EOC progression through targeting CDKN1B
by: Xiaoduan Li, et al.
Published: (2020-08-01)

Association between early risk factors and CDKN2A/B deletion in pediatric patients with acute lymphoblastic leukemia in a pediatric cancer center in Colombia
by: Cindy Martinez, et al.
Published: (2022-03-01)

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas
by: Daniel F. Marker, et al.
Published: (2020-10-01)

CDKN2BAS gene polymorphisms and the risk of intracranial aneurysm in the Chinese population
by: Yunchang Chen, et al.
Published: (2017-12-01)

Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis
by: Jing Chang, et al.
Published: (2020-12-01)

Retracted: Interference of the long noncoding RNA CDKN2B‐AS1 upregulates miR‐181a‐5p/TGFβI axis to restrain the metastasis and promote apoptosis and senescence of cervical cancer cells
by: Lihong Zhu, et al.
Published: (2019-04-01)

Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report
by: Vallari Shah, et al.
Published: (2017-11-01)

Evaluation of rs10811661 polymorphism in CDKN2A / B in colon and gastric cancer
by: Maria Beihaghi, et al.
Published: (2023-10-01)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
by: Andrea Forschner, et al.
Published: (2021-03-01)

Bioinformatics approaches to multi-omics analysis of the potential of CDKN2A as a biomarker and therapeutic target for uterine corpus endometrial carcinoma
by: Liang Ma, et al.
Published: (2025-01-01)

Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma
by: Chao Shang, et al.
Published: (2019-01-01)

Effects of CDKN2B‐AS1 polymorphisms on the susceptibility to coronary heart disease
by: Kang Huang, et al.
Published: (2019-11-01)

<i>CDKN2A</i> Gene Mutations: Implications for Hereditary Cancer Syndromes
by: Anastasiia Danishevich, et al.
Published: (2023-12-01)

Retinoic acid inhibition of cell proliferation via activation of CDKN1B signaling in the forebrain and spinal cord during mouse embryonic development
by: Ahmed Said, et al.
Published: (2024-11-01)

Clinical characteristics and prognosis of ALL in children with CDKN2A/B gene deletion
by: Yiyu Wang, et al.
Published: (2025-02-01)

CDKN2B-AS1 participates in high glucose-induced apoptosis and fibrosis via NOTCH2 through functioning as a miR-98-5p decoy in human podocytes and renal tubular cells
by: Min Xiao, et al.
Published: (2021-10-01)

Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter
by: Minghui Ou, et al.
Published: (2020-05-01)

Co‐occurrence of CDKN2A/B and IFN‐I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma
by: Yuan Peng, et al.
Published: (2022-04-01)

Primary adrenocortical carcinoma with mutation in the CDKN2A gene
by: Changming Dong, et al.
Published: (2023-09-01)